- Home
- STTK vs SEAT Comparison
STTK vs SEAT Comparison
Compare STTK & SEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- SEAT
- Stock Information
- Founded
- STTK 2016
- SEAT 2001
- Country
- STTK United States
- SEAT United States
- Employees
- STTK N/A
- SEAT N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- SEAT Industrial Machinery/Components
- Sector
- STTK Health Care
- SEAT Industrials
- Exchange
- STTK Nasdaq
- SEAT Nasdaq
- Market Cap
- STTK 83.8M
- SEAT 96.5M
- IPO Year
- STTK 2020
- SEAT N/A
- Fundamental
- Price
- STTK $1.92
- SEAT $17.02
- Analyst Decision
- STTK Hold
- SEAT Buy
- Analyst Count
- STTK 6
- SEAT 11
- Target Price
- STTK $2.67
- SEAT $68.00
- AVG Volume (30 Days)
- STTK 1.6M
- SEAT 121.2K
- Earning Date
- STTK 08-14-2025
- SEAT 11-06-2025
- Dividend Yield
- STTK N/A
- SEAT N/A
- EPS Growth
- STTK N/A
- SEAT N/A
- EPS
- STTK N/A
- SEAT N/A
- Revenue
- STTK $2,997,000.00
- SEAT $694,007,000.00
- Revenue This Year
- STTK N/A
- SEAT N/A
- Revenue Next Year
- STTK N/A
- SEAT N/A
- P/E Ratio
- STTK N/A
- SEAT N/A
- Revenue Growth
- STTK N/A
- SEAT N/A
- 52 Week Low
- STTK $0.69
- SEAT $14.54
- 52 Week High
- STTK $3.95
- SEAT $100.00
- Technical
- Relative Strength Index (RSI)
- STTK 72.13
- SEAT 42.67
- Support Level
- STTK $1.68
- SEAT $14.69
- Resistance Level
- STTK $2.04
- SEAT $16.71
- Average True Range (ATR)
- STTK 0.19
- SEAT 1.17
- MACD
- STTK 0.09
- SEAT 0.65
- Stochastic Oscillator
- STTK 89.29
- SEAT 69.80
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About SEAT Vivid Seats Inc.
Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada and Japan. It operates in two segments namely marketplace and resale. Marketplace segment, act as an intermediary between ticket buyers, sellers, and partners through which company earn revenue from processing ticket sales for live events and facilitating the booking of hotel rooms and packages on websites and mobile applications. Resale segment provides internal research and development support for Skybox and supplements ongoing efforts to deliver software and tools. Majority of revenue is from Marketplace segment.